Leading pharmaceutical executive Jennifer Fillman joins evidence-based solution provider Genesis Research as Chief Financial Officer

Loading...
Loading...

International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining Genesis, Ms. Fillman was Senior Vice President and CFO Clinical Solutions at Syneos Health.

HOBOKEN, N.J., Sept. 26, 2022 /PRNewswire-PRWeb/ -- International health economics and outcomes research (HEOR) and real-world evidence (RWE) organization Genesis Research has announced the appointment of Jennifer Fillman as its new Chief Financial Officer. Prior to joining Genesis, Ms. Fillman was Senior Vice President and CFO Clinical Solutions at Syneos Health.

Backed by healthcare investor GHO Capital, Genesis Research is an established leader in evidence strategy, development, and communication. Following its recent acquisition of payer research experts Market Access Transformation, Genesis Research continues to expand and refine its tech-enabled, fit-for-purpose evidence solutions: providing pharmaceutical, biotechnology, and medical device companies with a better way to develop impactful evidence solutions and optimize market access.

Jennifer Fillman is a highly respected executive with over 27 years of corporate, financial, and business experience. She also offers deep knowledge of the pharmaceutical industry, having worked as CFO for Syneos Heath's largest operating segment for the last three years and previously having served in a wide variety of roles at healthcare solutions provider Cardinal Health, including as general manager of four pharmaceutical business units.

Frank A. Corvino, Co-founder and CEO of Genesis Research, said: "Jennifer's experience in developing pharmaceutical business and her in-depth knowledge of the industry will be invaluable as we expand to meet the increasing demand for the agile, tech-enabled research partnerships we've introduced to the industry. I'm delighted to have her on our team."

Jennifer said: "I'm thrilled to join Genesis Research to use my experience in scaling pharma services businesses to help the company maximize its growth potential. Frank and the team have built an amazing organization. I'm humbled to be a part of it and am excited to see what we can grow together."

About Genesis Research:
Genesis Research is an international health economics and outcomes research and real-world evidence research organization that supports the life sciences industry. As a leader in evidence strategy, generation, and communication, the company also supports pharmaceutical and biotech clients with tech-enabled, dedicated partnerships delivered via a unique engagement model that enables life sciences companies to address complex needs with unmatched timeliness and quality. For more information, visit http://www.genesisrg.com or email solutions@genesisrg.com.

About GHO Capital:
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. The company applies global capabilities and perspectives to unlock high-growth healthcare opportunities, targeting Pan-European and transatlantic internationalization to build market-leading businesses of strategic global value. Its proven investment track record reflects the unrivaled depth of its industry expertise and network. The company partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit http://www.ghocapital.com.

Media Contact

Richard Chumbley, Genesis Research, 44 7985642245, rchumbley@genesisrg.com

 

SOURCE Genesis Research

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...